In the MDA-231 breast cancer cell line with mutant p53, R2 also decreased viability, but the significantly decreased viability was observed at higher dose than in cells with wild type p53: 50 μM in MDA-231 (Figure 2F) versus 20 μM in MCF-7 cells (Figure 2E). Here, TP53 is linked to breast cancer.